Clinical trial · no report yet · Phase 2
TROPiCS-03
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
- NCT03964727 ↗
- Active not recruiting
- Gilead Sciences
- 25 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 14 | |
| YouTube | 6 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Metastatic Solid Tumor
- Interventions
- Sacituzumab Govitecan-hziy
- Arms
- Cohort 1 Group 1: NSCLC [Adenocarcinoma + Squamous Cell Carcinoma (SCC)] · Experimental
- Cohort 1 Group 2: NSCLC (Adenocarcinoma) · Experimental
- Cohort 1 Group 3: NSCLC (SCC) · Experimental
- Cohort 2: Head And Neck Squamous Cell Carcinoma (HNSCC) · Experimental
- Cohort 3: Endometrial Cancer (EC) · Experimental
- Cohort 4: Extensive-Stage Small Cell Lung Cancer (ES-SCLC) · Experimental
- Enrollment
- 227
- Primary outcomes
- Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment
- Sponsor
- Gilead Sciences
- Start
- Oct 15, 2019
- Primary completion
- Jan 15, 2025
- Results posted
- Yes
- Registry record
- NCT03964727 · updated Apr 28, 2026
Publications
linked from the registry- Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin KW, Kuo P, Dumbrava EE. Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2024 Oct 10;42(29):3421-3429. doi: 10.1200/JCO.23.02767. Epub 2024 Jul 31. PubMed 39083724
- Michel L, Jimeno A, Sukari A, Beck JT, Chiu J, Ahern E, Hilton J, Even C, Zanetta S, Mekan S, Patel J, Wu T, Dumbrava EE. Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results from the Phase II TROPiCS-03 Basket Study. Clin Cancer Res. 2025 Mar 3;31(5):832-838. doi: 10.1158/1078-0432.CCR-24-2523. PubMed 39665770
- Dowlati A, Chiang AC, Cervantes A, Babu S, Hamilton E, Wong SF, Tazbirkova A, Sullivan IG, van Marcke C, Italiano A, Patel J, Mekan S, Wu T, Waqar SN. Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03. J Thorac Oncol. 2025 Jun;20(6):799-808. doi: 10.1016/j.jtho.2024.12.028. Epub 2025 Jan 2. PubMed 39755168